Novacyt SA's (AIM:NCYT, OTC:NVYTF, EPA:ALNOV) share price fell 16% following the announcement of a commercial settlement in its High Court case.
The molecular diagnostics company agreed to pay £5 million to the Department of Health and Social Care, resolving all claims and counterclaims.
As a result, the trial scheduled for this week will not proceed. Both parties deny any liability or wrongdoing.
The shares fell 11.2p to 58.6p.